$570 million for juvenile diabetes company

Israel’s Andromeda Biotech has been purchased by Hyperion Therapeutics for a total of $570 million. Andromeda’s DiaPep277 is a therapy for Type 1 (juvenile) diabetes. The drug is undergoing a Phase III clinical trial, with results due in the first quarter of 2015.

This entry was posted in Economy & Business. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *